Sugi Predict

Sugi Predict / Compounds / SCHEMBL837428

SCHEMBL837428

SCHEMBL837428

C=CCn1c(Cl)nc2c1c(=O)[nH]c(=O)n2CCCCC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.55
▸ KMT2A Q03164 6/20 0.55
▸ MAPK1 P28482 5/20 0.55
▸ HTT P42858 4/20 0.55
▸ HSD17B10 Q99714 3/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ TSHR P16473 3/20 0.49
▸ ALDH1A1 P00352 8/20 0.47
▸ HPGD P15428 3/20 0.47
▸ POLB P06746 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ XBP1 P17861 1/20 0.46
▸ RXFP1 Q9HBX9 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ MITF O75030 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ PAX8 Q06710 1/20 0.46
▸ GPR55 Q9Y2T6 1/20 0.46
▸ BRD4 O60885 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3121131 0.99 MEN1 (0.54) MEN1KMT2AMAPK1HTTHSD17B10
SCHEMBL835360 0.96 TSHR (0.52) MEN1KMT2AMAPK1HTTHSD17B10
SCHEMBL837415 0.91 TSHR (0.49) MEN1KMT2AMAPK1HTTHSD17B10
SCHEMBL3185456 0.88 ALDH1A1 (0.43) MEN1KMT2AMAPK1HTTHSD17B10
SCHEMBL836795 0.86 ALDH1A1 (0.49) MEN1KMT2AHTTHSD17B10ALDH1A1
SCHEMBL3103672 0.86 ALDH1A1 (0.44) MEN1KMT2AMAPK1HTTHSD17B10
SCHEMBL835813 0.83 ALDH1A1 (0.42) MEN1KMT2AMAPK1HTTHSD17B10
SCHEMBL19066313 0.83 ALDH1A1 (0.57) MEN1KMT2AMAPK1HTTHSD17B10
SCHEMBL23255226 0.83 TSHR (0.56) MEN1KMT2AMAPK1HTTHSD17B10
SCHEMBL3187590 0.83 TSHR (0.46) MEN1KMT2AMAPK1HTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3251675-B1 PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE SHANTON PHARMA PTE LTD (SG) 2021-04-21 — — EP disclosed
US-10322132-B2 Prevention or treatment of uratic or gouty diseases SHANTON PHARMA CO., LTD (CN) 2019-06-18 — — US disclosed
EP-3251675-A1 PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE Shanton Pharma Co., Ltd. (CN) 2017-12-06 — — EP disclosed
US-20170326148-A1 PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE Shanton Pharma Pte. Ltd. (SG) 2017-11-16 — — US disclosed
US-20170326148-A1 PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE Shanton Pharma Pte. Ltd. (SG) 2017-11-16 — — US disclosed
US-20170027945-A1 Novel Compounds GLAXOSMITHKLINE LLC 2017-02-02 — — US disclosed
US-20170027945-A1 Novel Compounds GLAXOSMITHKLINE LLC 2017-02-02 — — US disclosed
WO-2016119570-A1 PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE 上海珊顿医药科技有限公司 2016-08-04 — — WO disclosed
US-20150366870-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE LLC 2015-12-24 — — US disclosed
US-20150366870-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE LLC 2015-12-24 — — US disclosed
EP-1912991-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SmithKline Beecham Corporation (US) 2008-04-23 — — EP disclosed
EP-1912992-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SmithKline Beecham Corporation (US) 2008-04-23 — — EP disclosed
US-20070135456-A1 Medicaments with hm74a receptor activity GLAXOSMITHKLINE LLC 2007-06-14 — — US disclosed
US-20070135456-A1 Medicaments with hm74a receptor activity GLAXOSMITHKLINE LLC 2007-06-14 — — US disclosed
US-20070135456-A1 Medicaments with hm74a receptor activity GLAXOSMITHKLINE LLC 2007-06-14 — — US disclosed
EP-1781657-A2 MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2007-05-09 — — EP disclosed
WO-2007017262-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-02-15 — — WO disclosed
WO-2007017261-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-02-15 — — WO disclosed
WO-2006045564-A1 XANTHINE DERIVATIVES WITH HM74A RECEPTOR ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2006-05-04 — — WO disclosed
WO-2005077950-A2 MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135456-A1 Medicaments with hm74a receptor activity HCAR1, GPR84, HCAR3 MEN1 1560/4885KMT2A 2484/4885MAPK1 3299/4885
US-20170027945-A1 Novel Compounds GPR68, GPR84, GPR88 MEN1 2061/4885KMT2A 2720/4885MAPK1 1297/4885
US-20170326148-A1 PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE NLRP3, REN, SLC5A1 MEN1 2275/4885KMT2A 3290/4885MAPK1 1439/4885
US-10322132-B2 Prevention or treatment of uratic or gouty diseases REN, NLRP3, SLC5A1 MEN1 2223/4885KMT2A 3253/4885MAPK1 1596/4885
US-20150366870-A1 NOVEL COMPOUNDS GPR68, GPR84, GPR88 MEN1 2061/4885KMT2A 2720/4885MAPK1 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.